Jeremy S Abramson
Overview
Explore the profile of Jeremy S Abramson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
5337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johnson P, Abramson J, LaCasce A, Armand P, Barnes J, Merryman R, et al.
J Natl Compr Canc Netw
. 2025 Feb;
23(3).
PMID: 39970870
Background: Aggressive non-Hodgkin lymphoma (aNHL) is more common in older adults. Although chemoimmunotherapy can yield durable remissions, it is also associated with significant toxicities. Despite this, longitudinal studies assessing patient-reported...
2.
Toulmin S, Nazir H, Abramson J, Soumerai J, Freeman E
Leuk Lymphoma
. 2025 Jan;
1-3.
PMID: 39862062
No abstract available.
3.
Abramson J, Ku M, Hertzberg M, Huang H, Fox C, Zhang H, et al.
Lancet
. 2024 Nov;
404(10466):1940-1954.
PMID: 39550172
Background: Glofitamab monotherapy induces durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more previous therapies, but has not previously been assessed as a...
4.
Kaulen L, Karschnia P, Doubrovinskaia S, Abramson J, Martinez-Lage M, Shankar G, et al.
Am J Hematol
. 2024 Oct;
99(12):2411-2415.
PMID: 39440883
Lymphomatous infiltration of the peripheral nervous system (PNS), termed neurolymphomatosis, represents a distinct extranodal non-Hodgkin lymphoma variant with dismal outcome. CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy has emerged as...
5.
Kumar A, Soumerai J, Soumerai J, Abramson J, Barnes J, Caron P, et al.
Blood
. 2024 Oct;
145(5):497-507.
PMID: 39437708
TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated patients...
6.
Somasundaram E, Abramson J
Leuk Lymphoma
. 2024 Oct;
66(1):26-33.
PMID: 39378204
Double-hit lymphoma (DHL) is a high-risk subtype of large B-cell lymphoma, defined by concurrent rearrangements and . The diagnosis is confirmed through histologic and immunophenotypic examination and fluorescence hybridization (FISH)...
7.
Abramson J, Stuver R, Herrera A, Patterson E, Wen Y, Moskowitz A
Crit Rev Oncol Hematol
. 2024 Sep;
204:104499.
PMID: 39244180
The ECHELON-1 trial demonstrated the effectiveness of brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine as a frontline treatment regimen in classical Hodgkin lymphoma. However, peripheral neuropathy (PN)...
8.
Xu-Monette Z, Luo C, Yu L, Li Y, Bhagat G, Tzankov A, et al.
Oncoimmunology
. 2024 Aug;
13(1):2384667.
PMID: 39108501
Deficient (d) DNA mismatch repair (MMR) is a biomarker predictive of better response to PD-1 blockade immunotherapy in solid tumors. dMMR can be caused by mutations in MMR genes or...
9.
Haydu J, Abramson J
Blood Adv
. 2024 Jul;
8(17):4700-4710.
PMID: 39042891
T-cell engaging-therapies have transformed the treatment landscape of relapsed and refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients with historically limited therapeutic options. This review focuses on...
10.
Morschhauser F, Dahiya S, Palomba M, Garcia-Sancho A, Reguera Ortega J, Kuruvilla J, et al.
Nat Med
. 2024 Jul;
30(8):2374.
PMID: 38982297
No abstract available.